TY - JOUR
T1 - Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
AU - Larocca, Alessandra
AU - Dold, Sandra Maria
AU - Zweegman, Sonja
AU - Terpos, Evangelos
AU - Wäsch, Ralph
AU - D’Agostino, Mattia
AU - Scheubeck, Sophia
AU - Goldschmidt, Hartmut
AU - Gay, Francesca
AU - Cavo, Michele
AU - Ludwig, Heinz
AU - Straka, Christian
AU - Bringhen, Sara
AU - Auner, Holger W.
AU - Caers, Jo
AU - Gramatzki, Martin
AU - Offidani, Massimo
AU - Dimopoulos, Meletios A.
AU - Einsele, Hermann
AU - Boccadoro, Mario
AU - Sonneveld, Pieter
AU - Engelhardt, Monika
PY - 2018
Y1 - 2018
N2 - Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a particular challenge due to their marked heterogeneity. Many new and highly effective drugs have been introduced in the last few years and results from clinical trials are promising. Besides the availability of novel agents, a careful evaluation of elderly patients showed to be a key factor for the success of therapy. A geriatric assessment is a valid strategy to better stratify patients. In particular, different scores are available today to appropriately assess elderly patients and define their fitness/frailty status. The choice of treatment—transplantation, triplets, doublets, or reduced-dose therapies including novel agents—should depend on the patient’s fitness status (fit, intermediate-fit or frail). Second-generation novel agents have also been evaluated as salvage therapy in the elderly, and these new agents certainly represent a further step forward in the treatment armamentarium for elderly patients with multiple myeloma.
AB - Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a particular challenge due to their marked heterogeneity. Many new and highly effective drugs have been introduced in the last few years and results from clinical trials are promising. Besides the availability of novel agents, a careful evaluation of elderly patients showed to be a key factor for the success of therapy. A geriatric assessment is a valid strategy to better stratify patients. In particular, different scores are available today to appropriately assess elderly patients and define their fitness/frailty status. The choice of treatment—transplantation, triplets, doublets, or reduced-dose therapies including novel agents—should depend on the patient’s fitness status (fit, intermediate-fit or frail). Second-generation novel agents have also been evaluated as salvage therapy in the elderly, and these new agents certainly represent a further step forward in the treatment armamentarium for elderly patients with multiple myeloma.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048123109&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29880892
U2 - https://doi.org/10.1038/s41375-018-0142-9
DO - https://doi.org/10.1038/s41375-018-0142-9
M3 - Review article
C2 - 29880892
SN - 0887-6924
VL - 32
SP - 1697
EP - 1712
JO - Leukemia
JF - Leukemia
IS - 8
ER -